DRAIC mediates hnRNPA2B1 stability and m6A-modified IGF1R instability to inhibit tumor progression

Ya Wen1,2,3, Xiwang Yang2, Yifei Li2,4

  • 1Medical College, Guizhou University, Guiyang, 550025, China.

Oncogene
|May 29, 2024
PubMed

Insights

Downregulated RNA in Cancer (DRAIC) suppresses clear cell Renal Carcinoma (ccRCC) by stabilizing hnRNPA2B1, which then degrades IGF1R mRNA via m6A modification, inhibiting tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Type 1 insulin-like growth factor receptor (IGF1R) is crucial in cancer development.
  • The posttranscriptional regulation of IGF1R, particularly via N6-methyladenosine (m6A) modification, is not well understood.
  • Clear cell Renal Carcinoma (ccRCC) is a major subtype of kidney cancer with complex regulatory mechanisms.

Purpose of the Study:

  • To investigate the role of the lncRNA Downregulated RNA in Cancer (DRAIC) in ccRCC progression.
  • To elucidate the molecular mechanism by which DRAIC affects tumor growth and metastasis.
  • To identify potential therapeutic targets within the DRAIC regulatory pathway.

Main Methods:

  • Investigated the interaction between DRAIC and heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1).
  • Assessed the effect of DRAIC on hnRNPA2B1 protein stability and its interaction with E3 ligase FBXO11.
  • Analyzed the impact of the DRAIC/hnRNPA2B1 axis on m6A-modified IGF1R mRNA stability and ccRCC progression.
  • Identified specific m6A modification sites on IGF1R mRNA.

Main Results:

  • DRAIC was found to suppress tumor growth and metastasis in ccRCC.
  • DRAIC enhances hnRNPA2B1 protein stability by inhibiting FBXO11-mediated ubiquitination and degradation.
  • hnRNPA2B1 destabilizes m6A-modified IGF1R mRNA, thereby inhibiting ccRCC progression.
  • Four m6A modification sites on IGF1R mRNA were identified as critical for its degradation.

Conclusions:

  • The DRAIC/hnRNPA2B1 axis regulates IGF1R mRNA stability in an m6A-dependent manner.
  • This study reveals a novel mechanism linking m6A-modified RNA and ubiquitin-modified protein.
  • The DRAIC/hnRNPA2B1/FBXO11/IGF1R axis represents a promising therapeutic target for ccRCC treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.3K